围产期抑郁的雌激素敏感性证据:药理性性激素操纵研究
该研究基于60名接受促性腺激素释放激素激动剂(GnRHa)或安慰剂的女性,纵向采集基因表达与DNA甲基化数据,检验116个预测围产期抑郁(PND)的性类固醇反应性转录本在药理性激素诱导情绪变化模型中的表现。结果显示,GnRHa后早期和后期随访中均存在显著重叠(19%)的差异表达转录本,且PND基因与抑郁症状、雌二醇水平及新皮层5-羟色胺转运体结合变化相关。结论提示个体对雌激素的分子敏感性差异与激素诱导情绪变化的易感性相关,有望成为候选生物标志物。
要点
- 116个PND预测转录本中19%在GnRHa后早期和后期随访均差异表达,提示持续效应。
- GnRHa组中PND基因表达变化与抑郁症状变化相关者占28%,DNA甲基化变化相关者占66%。
- PND基因与雌二醇水平变化相关:基因表达49%,DNA甲基化66%。
核心结论
- 围产期抑郁预测转录本在药理性性激素操纵模型中呈现持续差异表达和DNA甲基化改变。
- 个体对雌激素的分子敏感性差异与激素诱导的情绪变化易感性相关,提示候选生物标志物潜力。
研究设计与样本
- 研究纳入60名女性,接受促性腺激素释放激素激动剂(GnRHa)或安慰剂,纵向采集全基因组基因表达和DNA甲基化数据。
- 采用线性混合效应模型评估GnRHa双相卵巢反应中基线至随访的基因表达和DNA甲基化差异。
主要发现
- 116个PND预测转录本中,19%在GnRHa后早期和后期随访均显著差异表达,提示持续效应。
- 49%的受检基因在GnRHa后后期随访时呈现差异甲基化。
- GnRHa组中,PND基因表达变化与抑郁症状变化显著相关者占28%,DNA甲基化变化相关者占66%。
- PND基因表达与雌二醇水平变化相关者占49%,DNA甲基化相关者占66%。
- PND基因表达与新皮层5-羟色胺转运体结合变化相关者占8%,DNA甲基化相关者占45%。
关键数值与推荐
- 116个预识别的性类固醇反应性转录本中,19%在GnRHa后早期和后期随访均差异表达。
- GnRHa后后期随访中49%的受检基因差异甲基化。
- GnRHa组中PND基因与抑郁症状变化相关:基因表达28%,DNA甲基化66%。
- GnRHa组中PND基因与雌二醇水平变化相关:基因表达49%,DNA甲基化66%。
- GnRHa组中PND基因与新皮层5-羟色胺转运体结合变化相关:基因表达8%,DNA甲基化45%。
临床怎么用
- 围产期抑郁风险预测可关注性类固醇反应性转录本的表达和甲基化变化。
- 个体对雌激素的分子敏感性差异可能辅助识别激素诱导情绪变化的高危人群。
- 雌激素相关生物变化与5-羟色胺信号变化的关联提示潜在机制路径。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Enhanced sensitivity to oestrogen signalling may drive increased risk for depressive symptoms when exposed to peripartum sex-steroid hormone fluctuations. AIM: Testing if 116 pre-identified sex steroid-responsive transcripts that predicted perinatal depression (PND) translates to a pharmacological model of hormone-induced mood changes. METHOD: We generated longitudinal, genome-wide gene-expression and DNA-methylation data from 60 women exposed to a gonadotrophin-releasing hormone agonist (GnRHa) or placebo. We used linear mixed-effect models to assess differences between baseline and follow-up for gene expression and DNA methylation in the biphasic ovarian response to GnRHa. RESULTS: Of the 116 PND-predictive transcripts, a significant (19%) overlap was observed with those differentially expressed post-GnRHa at both early and later follow-up, indicating sustained effects. Similarly, 49% of tested genes were differentially methylated post-GnRHa at the late follow-up. Within the GnRHa group, a large proportion of PND genes were significantly associated (gene expression; DNA methylation) with changes in depressive symptoms (28%; 66%), oestradiol levels (49%; 66%) and neocortex serotonin transporter binding (8%; 45%) between baseline and follow-up. CONCLUSIONS: Our data bridge clinical PND biomarkers with a pharmacological model of sex hormone-induced mood changes and directly relate oestrogen-induced biological changes with depressive symptoms and associated serotonin-signalling changes. Our data highlight that individual variations in molecular sensitivity to oestrogen associate with susceptibility to hormone-induced mood changes and hold promise for candidate biomarkers. DECLARATION OF INTEREST: V.G.F. received honorarium for being a speaker for H. Lundbeck A/S. E.B.B. receives research funding from Böhringer Ingelheim to investigate FKBP5 as a potential drug target for depression.
引用
- Mehta D, Rex-Haffner M, Søndergaard HB, et al. Evidence for oestrogen sensitivity in perinatal depression: pharmacological sex hormone manipulation study. Br J Psychiatry. 2019. PMID: 30457060. doi:10.1192/bjp.2018.234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。